5 Key Takeaways

• 1

  A second dose of Moderna’s mRNA-1345 RSV vaccine was well tolerated and produced comparable antibody responses at 24 months post-primary dose.

• 2

  The phase 3 study involved 1,502 participants aged 60 years or older, with a 2-to-1 random assignment to vaccine or placebo.

• 3

  Revaccination met noninferiority criteria for neutralizing antibody responses against RSV-A and RSV-B at 29 days post-administration.

• 4

  Solicited reactions were mostly mild or moderate, with injection-site pain, fatigue, and myalgia being the most common.

• 5

  The study did not evaluate vaccine efficacy post-revaccination and noted limitations, including few participants aged 80 years or older.